ArticleArthritis research & therapy2026
Characteristics and safety outcomes of rheumatoid arthritis patients treated with AMGEVITA
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOver the past decade, rheumatoid arthritis (RA) management in the UK has evolved with increased use of biologic and targeted synthetic Disease-Modifying Anti-Rheumatic Drugs (DMARDs). The introduction of biosimilars, including AMGEVITA®, has expanded treatment options and improved access for patients. This study aims to (1) describe the clinical characteristics and serious adverse events (SAEs) in RA patients treated with AMGEVITA®, and (2) similarly, describe the incidence of these outcomes from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis (BSRBR-RA) anti-tumor necrosis factor (anti-TNF) comparison cohort.
methodsThe BSRBR-RA is a national registry for patients with RA receiving biologic treatments, including anti-TNF inhibitors (e.g., adalimumab) and non-anti-TNF biologics, designed to evaluate the long-term safety and effectiveness of these agents in clinical practice. SAE analyses derived from an interim pharmacovigilance report on a subset of all AMGEVITA® and anti-TNF patients in the BSRBR-RA based on the Manchester Template Report. Eligible participants were ≥ 16 years of age with RA who registered in the registry within 6 months of initiating AMGEVITA®. Descriptive statistics were calculated for all variables of interest.
resultsFrom 01/01/2019 to 31/03/2022, 288 RA patients initiating AMGEVITA® were enrolled. Follow-up ended 30/11/2023. The mean (SD) age was 59.7 (12.0) years; 86 (28.0%) were male; and mean (SD) disease duration at initiation was 9.9 (9.8) years. Two-thirds of AMGEVITA® patients were biologically naïve and 9.8% were using steroids at initiation. The crude incidence rate of SAEs in the AMGEVITA® cohort was 9.6 per 1,000 patient-years (95% CI: 3.1–22.4), including 37.5 serious infections per 1,000 patient-years (95% CI: 95% CI: 23.2–57.3). For context, the anti-TNF comparator cohort had a crude SAE rate of 13.3 per 1,000 patient-years (95% CI: 10.6–16.5) and a serious infection rate of 49.1 per 1,000 patient-years (95% CI: 43.8–54.8).
conclusionThe crude incidence rates of SAEs and serious infections among AMGEVITA® users were within the range observed for the anti-TNF comparator cohort. These findings provide supportive real-world safety data, although differences in baseline characteristics and the absence of adjusted analyses should be considered when interpreting results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.